Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus

N. Jiang1*, M. Li1*, M. Zhang2, J. Xu3, L. Jiang4, L. Gong5, F. Wu6, J. Gu7, J. Zhao1, Y. Xiang1, Z. Wang1, Y. Zhao1, X. Zeng1*, CSTAR co-authors

1 Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China,
2 Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China,
3 Department of Rheumatology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China,
4 Department of Rheumatology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China,
5 Department of Rheumatology, the General Hospital of Tianjin Medical University, Tianjin, China,
6 Department of Rheumatology, Capital Institute of Pediatrics, Beijing, China,
7 Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

* These authors contributed equally to this work.
¶ Membership of the CSTAR co-authors is provided in the Acknowledgments.

OPEN ACCESS

Citation: Jiang N, Li M, Zhang M, Xu J, Jiang L, Gong L, et al. (2019) Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus. PLoS ONE 14(11): e0225516. https://doi.org/10.1371/journal.pone.0225516

Editor: Xu-jie Zhou, Peking University First Hospital, CHINA

Received: January 23, 2019
Accepted: November 6, 2019
Published: November 20, 2019

Copyright: © 2019 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information file.

Funding: This study was supported by grant numbers: 2017YFC0907601, 2017YFC0907602, 2017YFC0907603, 2008BAI59B02, 2012AA02A513, to Dr X Zeng, from Chinese National Key Technology R&D Program, Chinese National High Technology Research and Development Program, Ministry of Science and

Abstract

Objectives
To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE).

Methods
The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count <100,000/mm³ at enrollment. Severe thrombocytopenia was defined as the platelet count <50,000/mm³. The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated.

Results
Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with
thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%).

Conclusions
Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.

Introduction
Systemic lupus erythematosus (SLE) is a complicated autoimmune disease which can affect almost all systems and organs. Skin, muscle skeletal system, hematological system and kidney are most frequently involved systems in Chinese patients [1]. Thrombocytopenia (TP) is a common hematological disorder in patients with SLE. The prevalence is estimated to range from 10% to 40% according to published literatures [2–5].

The association between thrombocytopenia and characteristics of SLE patients has been investigated in several studies. Thrombocytopenia has been shown to be associated with other severe clinical manifestations and poor prognosis in patients with SLE [6–8]. However, multi-center data regarding thrombocytopenia in Chinese SLE patients are limited.

Chinese SLE Treatment and Research group (CSTAR), which is supported by Chinese National Key Technology Research and Development Program, developed the first on-line registry of Chinese patients with SLE. This registry has described major clinical characteristics and related manifestations in Chinese patients, such as pulmonary arterial hypertension and serositis [9–10]. It also provides the opportunity to investigate the epidemiological and clinical features of patients with SLE-related thrombocytopenia.

Methods
Patient recruitment
Based on the CSTAR online registry, the study was conducted at 104 high-rank rheumatology centers in 30 provinces across China. As the leading center, Peking Union Medical College Hospital (PUMCH) takes substantial responsibilities for the training, communication and funding for the registry. This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital (PUMCH), which was the leading research center. Most centers accepted Ethics Committees (EC) from PUMCH as the leading site, some approved by their own EC, included Beijing Tongren Hospital, the General Hospital of Tianjing Medical University, and the Second Affiliated Hospital of Guangzhou Medical College. Written informed consents were provided by all patients before their enrollments into the CSTAR registry. Between April 2009 and February 2010, the CSTAR registry recruited 2104 Chinese SLE patients who fulfilled the 1997 SLE classification criteria revised by the ACR [11].
### Definition of thrombocytopenia

Lupus-related thrombocytopenia was defined as the platelet count less than 100,000/mm$^3$ at baseline. The diagnosis was made only if other causes, such as primary hematological disorders, viral infection and drug-induced thrombocytopenia, were excluded by the physicians at enrollment. Patients with thrombocytopenia were further categorized as having mild or severe thrombocytopenia. The same definition of severe thrombocytopenia as the LUMINA cohort [6] (platelet count less than 50,000/mm$^3$) was used in this study. The recruitment and exclusion processes were shown in Fig 1.

### Data collection

All CSTAR centers used the same protocol-directed methods to provide uniform evaluations and to record the patients’ data. Investigators received training on diagnosis confirmation, disease activity evaluation, data input and data quality control. In this 6-year longitudinal study, demographic, clinical and laboratory data were collected. Systemic involvements, including neuropsychiatric SLE, vasculitis, arthritis, myositis, lupus nephritis, mucocutaneous lesions, pleuritic and fever, were defined according to the SLE Disease Activity Index (SLEDAI) [12]. Laboratory data included white blood cell counts, complement levels and autoantibodies.

![Fig 1. Recruitment and exclusion flowchart.](https://doi.org/10.1371/journal.pone.0225516.g001)
Antinuclear antibodies (ANA), anti-double-stranded (ds)DNA, anti-Smith (Sm), anti-SSA/Ro, anti-SSB/La, anti-ribonucleoprotein (RNP), anti-ribosomal (anti-r) RNP and anti-phospholipid antibodies were measured in all patients at local laboratories. SLE disease activity was evaluated in all patients by SLEDAI. Damage was measured with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) [13] at the last visit. Mortality was recorded within six years. Data were collected between April 2009 and March 2016. The authors did not have access to information that could identify individual participants during or after data collection.

Statistical analysis
A case-control approach was used to compare parameters between patients with and without thrombocytopenia, and between patients with severe thrombocytopenia and mild thrombocytopenia (platelet count less than 100,000/mm$^3$ but greater than or equal to 50,000/mm$^3$). All analyses were conducted using the SPSS 19.0 statistical package (SPSS, Chicago, USA). Variables were described using counts and/or percentages or medians and ranges. Student’s t-test was used to compare quantitative data. Chi-squared test was used for the comparison of categorical data between the two groups. Variables with $P$ values $<0.05$ in the univariate analyses were further investigated using multivariate binary logistic regression analysis. Mortality was compared between patients with and without thrombocytopenia, and between patients with severe thrombocytopenia and mild thrombocytopenia, respectively, using Kaplan-Meier survival analysis and multivariate Cox regression. $P$ values $<0.05$ were considered to be statistically significant.

Results
Patients and demographics
From April 2009 to February 2010, 2104 Chinese patients with SLE who fulfilled four or more of the 1997 ACR revised SLE classification criteria were registered into the CSTAR cohort. Of these patients, 342 (16.3%) had thrombocytopenia at baseline. In patients with thrombocytopenia, mean (SD) platelet count was 78.8 (65.1) $\times 10^9$/mm$^3$, mean (SD) age at onset was 30.5 (12.1) years, age at diagnosis was 32.0 (12.4) years. The mean (SD) disease duration was 41.5 (64.6) months. As shown in Table 1, there was no significant difference in age, gender or disease duration between patients with thrombocytopenia and those without.

Clinical manifestations
The clinical manifestations are shown in Table 1. In univariate analysis, the prevalence of neurological involvement, vasculitis, myositis, nephritis, mucocutaneous involvement, pleuritic and fever were significantly higher in patients with thrombocytopenia than those without ($P<0.05$).

Laboratory findings
As shown in Table 2, the prevalence of leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia in univariate analysis.

SLE disease activity
SLEDAI was significantly higher in thrombocytopenia group than in non-thrombocytopenia group (13.2±7.5 vs. 9.0±6.7, $p<0.001$).
Multivariate analysis revealed that leukocytopenia, lupus nephritis, hypocomplementemia and elevated SLEDAI were independent related factors of thrombocytopenia in patients with SLE (all \( p < 0.05 \)), as shown in Table 3.

Prognosis

Of 2104 patients, 1494 had long-term follow-up data. No difference in damage at last visit was observed between thrombocytopenia (\( n = 226 \)) and non-thrombocytopenia (\( n = 1268 \)) group (0.36\( \pm \)0.66 vs. 0.30\( \pm \)0.60, \( p = 0.168 \)). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2\% vs. 95.5\%, \( p < 0.001 \), as shown in Fig 2). In multivariate Cox regression (Table 4), thrombocytopenia, sex, age of onset, disease duration, baseline damage and factors related with TP (nephritis, leukocytopenia, Table 1. Demographic and clinical features of patients with or without thrombocytopenia.

|                      | Thrombocytopenia | P value |
|----------------------|------------------|---------|
| Platelet count (1,000/mm\(^3\)) | Yes (\( n = 342 \)) | No (\( n = 1762 \)) |         |
| Sex, female          | 311 (90.9\%)     | 1603 (91.0\%) | 0.981   |
| Age at onset (years) | 30.5\( \pm \)12.1 | 29.4\( \pm \)12.3 | 0.150   |
| Age at diagnosis (years) | 32.0\( \pm \)12.4 | 30.5\( \pm \)12.5 | 0.056   |
| Disease duration (months) | 41.5\( \pm \)64.6 | 42.1\( \pm \)57.7 | 0.874   |
| NPSLE                | 29 (8.5\%)       | 89 (5.1\%)    | 0.012   |
| Vasculitis           | 36 (10.5\%)      | 107 (6.1\%)   | 0.003   |
| Arthritis            | 95 (27.8\%)      | 537 (30.5\%)  | 0.319   |
| Myositis             | 13 (3.8\%)       | 35 (2.0\%)    | 0.040   |
| Lupus nephritis      | 195 (57.0\%)     | 654 (37.1\%)  | \(<0.001\) |
| Mucocutaneous inclusion | 195 (57.0\%)   | 893 (50.7\%)  | 0.032   |
| Pleuritis            | 48 (14.0\%)      | 149 (8.5\%)   | \(<0.001\) |
| Fever                | 99 (28.9\%)      | 352 (20.0\%)  | \(<0.001\) |

NPSLE: neuropsychiatric systemic lupus erythematosus.

Table 2. Laboratory findings of patients with or without thrombocytopenia.

|                      | Thrombocytopenia | P value |
|----------------------|------------------|---------|
| Leukocytopenia       | 152 (44.4\%)     | 352 (20.0\%) | \(<0.001\) |
| Hypocomplementemia   | 280 (81.9\%)     | 1119 (63.5\%) | \(<0.001\) |
| ANA                  | 334 (97.7\%)     | 1730 (98.2\%) | 0.517   |
| Anti-dsDNA           | 95 (27.8\%)      | 519 (29.5\%) | 0.532   |
| Anti-Sm              | 65 (19.0\%)      | 284 (16.1\%) | 0.189   |
| Anti-RNP             | 29 (8.5\%)       | 160 (9.1\%)  | 0.722   |
| Anti-SSA/Ro          | 93 (27.2\%)      | 407 (23.1\%) | 0.104   |
| Anti-SSB/La          | 40 (11.7\%)      | 184 (10.4\%) | 0.492   |
| Anti-rRNP            | 41/165 (24.8\%)  | 212/847 (25.0\%) | 0.959   |
| APL                  | 88/175 (50.3\%)  | 326/760 (42.9\%) | 0.076   |

ANA: anti-nuclear antibodies; anti-dsDNA: anti-double-stranded DNA; anti-RNP: anti-ribonucleoprotein; anti-rRNP: anti-ribosomal RNP; anti-Sm: anti-Smith; APL: anti-phospholipid.
hypocomplementemia and SLEDAI) were analyzed. Male sex, older age of onset, and nephritis at baseline were revealed to be risk factors of mortality.

**Comparison of patients with severe and mild thrombocytopenia**

As shown in Table 5, 95 patients (27.8%) had severe thrombocytopenia. Of these patients, 87 (91.6%) were female. Their mean (SD) platelet count was 23.4 (14.2) ×10^9/mm^3, mean (SD) age at onset was 31.9 (12.2) years, age at diagnosis was 33.5 (12.2) years. Their mean (SD) disease duration was 60.9 (80.8) months, which was obviously longer than patients with mild thrombocytopenia. There was no significant difference in age or gender between patients with severe or mild thrombocytopenia. The prevalence of nephritis and mucocutaneous involvement were significantly lower in patients with severe thrombocytopenia than patients with mild thrombocytopenia (P < 0.05).

As shown in Table 6, the prevalence of leukocytopenia, hypocomplementemia, positive anti-dsDNA and anti-rRNP antibodies were significantly lower in patients with severe thrombocytopenia in univariate analysis (P < 0.05).

SLEDAI was significantly lower in severe thrombocytopenia group than in mild thrombocytopenia group (11.2±7.5 vs. 14.0±7.4, p = 0.002). Baseline SDI was significantly lower in severe thrombocytopenia group than in mild thrombocytopenia group (0.08±0.32 vs. 14.0±7.4, p = 0.002).

As shown in Table 7, further multivariate analysis revealed that long disease duration was an independent risk factor of severe thrombocytopenia. Anti-rRNP was an independent protective factor of severe thrombocytopenia in patients with SLE.

No difference in SDI at last visit was observed between patients with severe thrombocytopenia (n = 66) and mild thrombocytopenia (n = 160) (0.21±0.57 vs. 0.34±0.60, p = 0.141). The 6-year survival showed no difference between patients with severe and mild thrombocytopenia (88.3% vs. 87.8%, p = 0.947, as shown in Fig 3). In multivariate Cox regression (Table 8), severe or mild thrombocytopenia, sex, age of onset, disease duration, baseline damage and factors related with TP (nephritis, leukocytopenia, hypocomplementemia and SLEDAI) were analyzed. Only long disease duration was revealed to be a risk factor of mortality.

**Discussion**

This study is a longitudinal observational study on the prevalence and clinical characteristics of SLE-related thrombocytopenia in Chinese patients with SLE. The results showed that

### Table 3. Multivariable analysis on related factors of thrombocytopenia in SLE

|                          | Odds ratio (95% CI) | P value |
|--------------------------|---------------------|---------|
| NPSLE                    | 1.155 (0.697–1.914) | 0.577   |
| Vasculitis               | 1.157 (0.730–1.832) | 0.535   |
| Myositis                 | 1.281 (0.637–2.575) | 0.487   |
| Lupus nephritis          | 1.539 (1.121–2.111) | 0.008   |
| Mucocutaneous involvement | 0.831 (0.633–1.092) | 0.185   |
| Pleuritis                | 1.041 (0.709–1.527) | 0.838   |
| Fever                    | 1.034 (0.775–1.380) | 0.821   |
| Leukocytopenia           | 2.644 (2.035–3.435) | < 0.001 |
| Hypocomplementemia       | 1.497 (1.077–2.082) | 0.016   |
| SLEDAI                   | 1.318 (1.069–1.624) | 0.010   |

NPSLE: neuropsychiatric systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.

https://doi.org/10.1371/journal.pone.0225516.t003
leukocytopenia, lupus nephritis, hypocomplementemia and elevated SLEDAI were independently associated with thrombocytopenia. The 6-year survival of patients with thrombocytopenia was significantly lower than those without. Long disease duration was an independent risk factor of severe thrombocytopenia, while anti-rRNP was an independent protective factor of severe thrombocytopenia.

Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence is consistent with data from a Latin American cohort [5] and a US cohort [6]. Patients with thrombocytopenia tended to be younger in previous reports [6,14], but in our study there is no difference in age, gender or disease duration between patients with and without thrombocytopenia.

In clinical practice, we found that patients with thrombocytopenia often have active disease and other organ involvements. Results of the study approved this clinical experience. The SLE
disease activity was assessed with SLEDAI, which was significantly higher in thrombocytopenia group in both univariable and multivariable analyses, indicating that patients with thrombocytopenia had more active disease. Univariable analysis revealed patients with thrombocytopenia tended to have more serious disease manifestations, including neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous involvements, pleuritis, fever and leukocytopenia. Lupus nephritis and leukocytopenia were shown to be independently risk factors of thrombocytopenia in multivariable analysis. As we know, hypocomplementemia indicates active SLE, and is associated with lupus nephritis. Therefore, it is stand to reason that hypocomplementemia and lupus nephritis were revealed as independent risk factors of thrombocytopenia in this study. Thrombocytopenia is often accompanied by other hematologic disorders in clinical practice. In a Latin American cohort, SLE-related thrombocytopenia was found to be associated with previous thrombocytopenia and autoimmune hemolytic anemia [5]. In our study we found leukocytopenia was a strong predictor of thrombocytopenia in patients with SLE. The result is in accordance with clinical experience.

Table 4. Multivariate Cox regression on risk factors of mortality in patients with SLE.

| P value | RR     | 95% CI of RR |
|---------|--------|--------------|
|         | Lower limit | Upper limit  |
| Sex (male) | 0.003 | 3.491 | 1.521 | 8.013 |
| Age of onset | 0.001 | 1.042 | 1.017 | 1.069 |
| Disease duration | 0.476 | 1.027 | .954 | 1.106 |
| Lupus nephritis | 0.019 | 3.096 | 1.204 | 7.962 |
| Leukocytopenia | 0.224 | 1.683 | 0.728 | 3.891 |
| Hypocomplementemia | 0.285 | 0.622 | 0.260 | 1.485 |
| SLEDAI | 0.741 | 0.989 | 0.924 | 1.058 |
| Baseline damage | 0.139 | 1.872 | 0.815 | 4.301 |
| Thrombocytopenia | 0.517 | 1.346 | 0.548 | 3.306 |

RR: relative risk; CI: confidence interval; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.

https://doi.org/10.1371/journal.pone.0225516.t004

Table 5. Demographic and clinical features of patients with mild or severe thrombocytopenia.

| Thrombocytopenia | Severe (n = 95) | Mild (n = 247) | P value |
|------------------|-----------------|----------------|---------|
| Platelet count (1,000/mm³) | 23.4±14.2 | 74.6±14.1 | 0.797 |
| Sex, female | 87 (91.6%) | 224 (90.7%) | 0.219 |
| Age at onset (years) | 31.9±12.2 | 30.0±12.2 | 0.172 |
| Age at diagnosis (years) | 33.5±12.2 | 31.5±12.5 | 0.005 |
| Disease duration (months) | 60.9±80.8 | 34.0±55.6 | 0.005 |
| NPSLE | 8 (8.4%) | 21 (8.5%) | 0.981 |
| Vasculitis | 9 (9.5%) | 27 (10.9%) | 0.694 |
| Arthritis | 24 (25.3%) | 71 (28.7%) | 0.520 |
| Myositis | 1 (1.1%) | 12 (4.9%) | 0.183 |
| Lupus nephritis | 46 (48.4%) | 149 (60.3%) | 0.046 |
| Mucocutaneous involvement | 44 (46.3%) | 151 (61.1%) | 0.013 |
| Pleuritis | 11 (11.6%) | 37 (15.0%) | 0.417 |
| Fever | 21 (22.1%) | 78 (31.6%) | 0.084 |

NPSLE: neuropsychiatric systemic lupus erythematosus.

https://doi.org/10.1371/journal.pone.0225516.t005
The association between APL and thrombocytopenia has been reported in the literatures [5–6,15–16]. In this study, the association between APL and thrombocytopenia was not proved, but some tendency was observed (p = 0.076). As we know, thrombocytopenia secondary to SLE occurs in several clinical situations, including immunologic thrombocytopenic purpura (ITP), antiphospholipid syndrome (APS), macrophage activation syndrome (MAS), thrombotic thrombocytopenic purpura (TTP), etc. Theoretically, some of the conditions are not related to APL. We infer this is the reason that the incidences of APL showed no disparity in the thrombocytopenia and non-thrombocytopenia groups in our study. Further analysis of the characteristics of populations with different causes of SLE–related thrombocytopenia may provide more details. The associations between thrombocytopenia and other autoantibodies, such as anti-dsDNA, anti-Sm, anti-SSA and anti-RNP antibodies, had been variably reported in the literatures [5–6,14,17]. These associations were not observed in our data. The differences were probably due to distinct ethnic groups and varied disease stages in different cohorts. 

As for prognosis, Kaplan-Meier survival analysis showed that patients with thrombocytopenia had a significantly lower long-term survival, indicating patients with SLE-related thrombocytopenia have a worse prognosis. In multivariate Cox regression analysis, thrombocytopenia was not found to be an independent prognostic factor. Since some of the known confounders,

### Table 6. Laboratory findings of patients with mild or severe thrombocytopenia.

|                | Severe (n = 95) | Mild (n = 247) | P value |
|----------------|----------------|---------------|---------|
| Leukocytopenia | 30 (31.6%)     | 122 (49.4%)   | 0.003   |
| Hypocomplementemia | 69 (72.6%) | 211 (85.4%) | 0.006   |
| ANA            | 91 (95.8%)     | 243 (98.4%)   | 0.307   |
| Anti-dsDNA     | 12 (12.6%)     | 83 (33.6%)    | <0.001  |
| Anti-Sm        | 13 (13.7%)     | 52 (21.1%)    | 0.120   |
| Anti-RNP       | 8 (8.4%)       | 21 (8.5%)     | 0.981   |
| Anti-SSA/Ro    | 25 (26.3%)     | 68 (27.5%)    | 0.821   |
| Anti-SSB/La    | 12 (12.6%)     | 28 (11.3%)    | 0.738   |
| Anti-rRNP      | 3/39 (7.7%)    | 38/128 (29.7%)| 0.005   |
| APL            | 26/50 (52.0%)  | 62/125 (49.6%)| 0.774   |

ANA: anti-nuclear antibodies; anti-dsDNA: anti-double-stranded DNA; anti-RNP: anti-ribonucleoprotein; anti-rRNP: anti-ribosomal RNP; anti-Sm: anti-Smith; APL: anti-phospholipid.

https://doi.org/10.1371/journal.pone.0225516.t006

### Table 7. Multivariable analysis on related factors of severe thrombocytopenia in patients with systemic lupus erythematosus.

|                                | Odds ratio (95% CI) | P value |
|--------------------------------|---------------------|---------|
| Disease duration (months)      | 1.006 (1.000–1.012) | 0.041   |
| Lupus nephritis                | 0.590 (0.202–1.703) | 0.335   |
| Mucocutaneous involvement      | 0.967 (0.368–2.539) | 0.945   |
| Leukocytopenia                 | 0.923 (0.352–2.419) | 0.871   |
| Hypocomplementemia             | 0.561 (0.194–1.626) | 0.287   |
| Anti-dsDNA                     | 0.348 (0.092–1.316) | 0.120   |
| Anti-rRNP                      | 0.208 (0.054–0.802) | 0.023   |
| SLEDAI                         | 0.950 (0.855–1.056) | 0.343   |

anti-dsDNA: anti-double-stranded DNA; anti-RNP: anti-ribonucleoprotein; anti-rRNP: anti-ribosomal RNP.

https://doi.org/10.1371/journal.pone.0225516.t007
such as poverty and cumulative steroid dose, were not included in our study, the conclusion is to be clarified in further studies. At the last visit, thrombocytopenia was not associated with damage accrual in our cohort. Similar results were observed in the LUMINA cohort [6] and the GLADEL cohort [5]. It was a limitation that bleeding events were not recorded in our study. By adding these data in future follow-ups in CSTAR cohort, we would have more information for understanding the relationship between thrombocytopenia and the prognosis of SLE.

When comparing the different characteristics of severe and mild thrombocytopenia, we found that severe thrombocytopenia tended to occur in patients with longer disease duration. In univariate analysis, lupus nephritis, mucocutaneous involvement, leukocytopenia, hypocomplementemia, anti-dsDNA antibody, anti-ribosome RNP antibody and elevated SLEDAI appeared to be protective for the patients against severe thrombocytopenia. Moreover, none of the clinical or laboratory factors showed higher incidence in patients with severe thrombocytopenia. Since hypocomplementemia, positive anti-dsDNA antibody and elevated SLEDAI
indicate active SLE, we can infer that severe thrombocytopenia was inclined to occur in patients with relatively low disease activity. Fernández et al found disease activity measured by the SLAM-R score was associated with thrombocytopenia, but not with severe thrombocytopenia (platelet count $< 50,000$/$\text{mm}^3$) [6], which were very consistent with the results in our study. It is widely accepted that anti-rRNP is related to neuropsychiatric involvement. Thus, the protective effect of lupus nephritis, mucocutaneous involvement, leukocytopenia and positive anti-rRNP observed in this study indicated that severe thrombocytopenia tended to occur in patients with few other organ involvements. In multivariable logistic analysis, the protective relationship was observed in anti-rRNP, suggesting that patients with negative anti-rRNP should be intensively monitored of developing severe thrombocytopenia. More observations are needed to confirm the relationship between severe thrombocytopenia and anti-rRNP or organ involvements. When analyzing the prognosis, both mortality and damage at last visit were not different in patients with mild or severe thrombocytopenia, indicating the possible similar disease outcome in the two populations. In multivariate Cox regression in patients with SLE-related thrombocytopenia, severe thrombocytopenia was not an independent risk factor of mortality comparing to mild thrombocytopenia. Long disease duration was revealed to be a risk factor of mortality, indicating that patients with thrombocytopenia and long term SLE need to be carefully monitored. In LUMINA cohort, severe thrombocytopenia (compared with all the SLE patients with platelet count $\geq 50,000$/$\text{mm}^3$, not with patients with mild thrombocytopenia) was found to be independently associated with damage accrual at the last visit, which was not observed in our study (data not shown). More observations are needed in future studies to confirm whether severe thrombocytopenia is associated with damage accrual.

The study has some limitations. First, the definition of thrombocytopenia in our study was based on short-term results of platelet count at baseline. Characteristics of patients with refractory thrombocytopenia was not investigated. Second, we did not have data regarding autoimmune hemolytic anemia (AIHA) and actual etiology of thrombocytopenia (i.e., anti-phospholipid syndrome, thrombotic thrombocytopenic purpura, immune thrombocytopenic purpura) in this study, since they were not included in the CSTAR cohort. Third, antiplatelet antibodies were not tested in this study, since the test were not available in some centers.

In conclusion, this study is a report of SLE-related thrombocytopenia with so far the largest sample size. We described the prevalence and clinical features of thrombocytopenia in patients from 30 provinces across China. Data indicated that thrombocytopenia was a common manifestation of SLE, and was associated with leukocytopenia, lupus nephritis and high disease

Table 8. Multivariate Cox regression on risk factors of mortality in patients with SLE-related TP.

|                          |   |   |     |                  |      |     |
|--------------------------|---|---|-----|------------------|------|-----|
|                          | P value | RR | 95% CI of RR |    |      |
|                          |          |    | Lower limit | Upper limit |    |      |
| Sex (male)               | 0.294    | 2.017 | 0.543 | 7.487          |    |      |
| Age of onset             | 0.170    | 1.026 | 0.989 | 1.064          |    |      |
| Disease duration         | **0.025**| 1.006 | 1.001 | 1.011          |    |      |
| Lupus nephritis          | 0.531    | 0.734 | 0.279 | 1.931          |    |      |
| Leukocytopenia           | 0.338    | 0.632 | 0.247 | 1.615          |    |      |
| Hypocomplementemia       | 0.128    | 0.483 | 0.189 | 1.233          |    |      |
| SLEDAI                   | 0.539    | 1.023 | 0.952 | 1.099          |    |      |
| Baseline damage          | 0.330    | 1.636 | 0.608 | 4.407          |    |      |
| Thrombocytopenia         | 0.484    | 0.702 | 0.260 | 1.894          |    |      |

RR: relative risk; CI: confidence interval; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.

https://doi.org/10.1371/journal.pone.0225516.t008
activity. Severe thrombocytopenia tended to occur in long-term and relatively quiet SLE, which has few other systemic involvement and low disease activity. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia. Patients with SLE-related thrombocytopenia has a decreased survival rate.

Supporting information

S1 File. STROBE_checklist.
(DOCX)

S2 File. Minimal Anonymized Data.
(XLSX)

Acknowledgments

We would like to thank CSTAR co-authors as following for assistance with the collections of cases.

^ CSTAR co-authors:
    Lead author: Dr. X Zeng, Peking Union Medical College Hospital, email: zengxfpumc@163.com
1. Peking Union Medical College Hospital: Hongmei Song, Xuejun Zeng, Wen Zhang, Xiaomei Leng, Qingjun Wu, Jinmei Su, Qun Shi, Xin You, Wenjie Zheng, Ying Jiang, Dong Xu, You Hou, Min Shen, Hua Chen, Xiaodan Gan, Chaojun Hu, Suxian Liu.
2. The Affiliated Drum Tower Hospital of Nanjing University Medical School: Lingyun Sun.
3. Anhui Provincial Hospital: Xiangpei Li, Xiaomei Li.
4. The Affiliated Hospital of Bengbu Medical College: Changhao Xie.
5. The First Affiliated Hospital of Sun Yat-sen University: Xiuyan Yang.
6. The Second Hospital of Shanxi Medical University: Xiaofeng Li, Jinli Ru.
7. Beijing Hospital Affiliated to the Ministry of Health of PRC: Cibo Huang, Bei Lai.
8. China-Japan Friendship Hospital Affiliated to the Ministry of Health of PRC: Donghai Wu.
9. Beijing Chao-Yang Hospital, Capital Medical University: Yi Zheng, Xiaohong Wen.
10. Xuanwu Hospital Affiliated to Capital Medical University: Xiaoxia Li.
11. Beijing Friendship Hospital Affiliated to Capital Medical University: Ting Duan.
12. Beijing Children Hospital Affiliated to Capital Medical University: Caifeng Li.
13. Capital Institute of Pediatrics: Fengqi Wu.
14. Chinese People's Liberation Army General Hospital: Feng Huang, Jian Zhu.
15. Changzheng Hospital Affiliated to the Second Military Medical University: Dongbao Zhao.
16. Changzheng Hospital Affiliated to the Second Military Medical University: Huji Xu.
17. Huashan Hospital Affiliated to Fudan University: Hejian Zou, Haomin Qiu.
18. The First Affiliated Hospital of Anhui Medical University: Jianhua Xu, Li Mu.
19. Qilu Hospital of Shandong University: Xingfu Li.
20. The Second Affiliated Hospital of Zhejiang University School of Medicine: Huaxiang Wu.
21. The Third Affiliated Hospital of Sun Yat-sen University: Jieruo Gu, Ou Jin.
22. The Second Affiliated Hospital of Guangzhou Medical College: Yi Tao.
23. Guangdong Provincial People’s Hospital: Xiao Zhang, Guangfu Dong.
24. Xiangya Hospital, Central South University: Xiaoxia Zuo, Yisha Li.
25. The First Affiliated Hospital of Harbin Medical University: Zhiyi Zhang, Yifang Mei.
26. The First Hospital of China Medical University: Weiguo Xiao, Hongfeng Zhang.
27. Xijing Hospital Affiliated to the Fourth Military Medical University: Ping Zhu, Zhenbiao Wu.
28. The Second Hospital of Lanzhou University: Yi Wang.
29. West China Hospital Affiliated to Sichuan University: Yi Liu.
30. The Affiliated Hospital of North Sichuan Medical College: Guohua Yuan.
31. Sichuan Provincial People’s Hospital: Bin Zhou.
32. The People’s Hospital of Xinjiang Autonomous Region: Lijun Wu.
33. Jiangsu Provincial People’s Hospital: Miaojia Zhang.
34. The First Affiliated Hospital of Zhengzhou University: Shengyun Liu.
35. Shengjing Hospital Affiliated to China Medical University: Ning Zhang.
36. The First Affiliated Hospital of Shantou University Medical College: Qingyu Zeng.
37. Tianjin First Central Hospital: Wencheng Qi, Feng Han.
38. The Affiliated Hospital of Bengbu Medical College: Zhijun Li, Changhao Xie.
39. Peking University First Hospital: Zhuoli Zhang, Yu Wang.
40. Peking University Shougang Hospital: Shuling Han.
41. Beijing Jishuitan Hospital: Hui Song, Shumin Yan.
42. Fuxing Hospital Affiliated to Capital Medical University: Wen Luo, Peilin Li.
43. Beijing Shunyi Hospital: Xiaomin Liu.
44. Peking University Third Hospital: Xiangyuan Liu, Xiaoli Deng.
45. South-West Hospital Affiliated to Third military Medical University: Yongfei Fang.
46. The First People’s Hospital of Foshan: Guoqiang Chen.
47. Fujian Provincial Hospital: He Lin.
48. The Second Affiliated Hospital of Fujian Medical University: Ling Lin.
49. Fuzhou General Hospital of Nanjing Military Region: Yinong Li.
50. Zhongshan Hospital Affiliated to Fudan University: Lindi Jiang, Lili Ma.
51. The First Affiliated Hospital of Guangxi Medical University: Cheng Zhao, Zhanrui Chen.
52. The People’s Hospital of Guangxi Autonomous Region: Jinying Lin.
53. The Affiliated Hospital of Guiyang Medical College: Long Li.
54. The Second Affiliated Hospital of Harbin Medical University: Yinhuan Zhao.
55. Hainan Provincial People’s Hospital: Feng Zhan, Shudian Lin.
56. Hebei Provincial People’s Hospital: Fengxiao Zhang, Yonglong Yan.
57. Bethune International Peace Hospital: Zhenbin Li.
58. Henan Provincial People’s Hospital: Fengmin Shao, Wei Liu.
59. The First Hospital of Qiqihar: Xiaowei Gong.
60. Tongji Hospital Affiliated to Tongji Medical School of Huazhong University of Science and Technology: Shaoxian Hu.
61. Jiangxi Provincial People’s Hospital: Youlian Wang.
62. No.202 Hospital of People’s Liberation Army: Yiping Lin, Lin Guo.
63. The Affiliated Hospital of Inner Mongolia Medical College: Hongbin Li.
64. Nanfang Hospital Affiliated to Southern Medical University: Min Yang.
65. The General Hospital of Ningxia Medical University: Yi Gong, Hong Zhu.
66. The Affiliated Hospital of Qingdao University Medical College: Jibo Wang.
67. The Fourth People’s Hospital of Shenzhen Affiliated to Guangdong Medical College: Zhizhong Ye, Zhihua Yin.
68. The General Hospital of Tianjin Medical University: Lu Gong.
69. Beijing Tongren Hospital Affiliated to Capital Medical University: Zhengang Wang, Li Cui.
70. The Second People’s Hospital of Wuxi: Tianli Ren.
71. The People’s Hospital of Wuxi: Yaohong Zou.
72. The Second Xiangya Hospital of Central South University: Jinwei Chen, Ni Mao.
73. The First People’s Hospital of Yunnan Province: Qin Li.
74. The First Affiliated Hospital of Zhejiang University School of Medicine: Jin Lin.
75. SunYat-sen Memorial Hospital, SunYat-sen University: Lie Dai, Baiyu Zhang.
76. The First People’s Hospital of Changzhou: Min Wu, Wen Xie.
77. The Affiliated Orthopaedic Hospital of Shandong Linyi People’s Hospital: Zhenchun Zhang.
78. Zhejiang Provincial People’s Hospital: Zhenhua Ying.
79. The First Affiliated Hospital of Baotou Medical College: Yongfu Wang.
80. The Affiliated Hospital of Nantong University: Zhanyun Da, Genkai Guo.
81. The First Affiliated Hospital of Suzhou University: Zhiwei Chen.
82. Beijing Shijitan Hospital: Miansong Zhao.
83. Shandong Yantai Yuhuangding Hospital: Weiling Yuan.
84. The General Hospital of Daqing Oilfield: Xiangjie Bi.
85. First Affiliated Hospital of Medical College of Xi’an Jiaotong University: Lan He, Dan Pu.
86. Provincial Hospital Affiliated to Shandong University, Jinan, China: Yuanchao Zhang, Limin Zhang.
87. Ji’nan University 2nd Clinical Medicine College, Shenzhen People’s Hospital: Dongzhou Liu, Xiaoping Hong.
88. No.285 Hospital of People’s Liberation Army: Zhu Chen.
89. The First Hospital of Shanxi Medical University: Xiumei Liu, Yiqun Hao.
90. Kailuan Hospital Affiliated to North China Coal Medical College: Liufu Cui.
91. Peking University Shenzhen Hospital: Qingwen Wang, Yi-Sheng Zhu.
92. The First Affiliated Hospital of Fujian Medical University: Junmin Chen.
93. The First Hospital of Ningbo: Xiafei Xi.
94. Shanxi Provincial People’s Hospital: Lihua Fang.
95. The Second Hospital of Hebei Medical University: Hongtao Jin, Huifang Guo.
96. The First Affiliated Hospital of Wenzhou Medical College: Xiaochun Zhu.
97. The Third Affiliated Hospital of Hebei Medical University: Ping Wei.
98. The First Affiliated Hospital of Xinjiang Medical University: Li Wei.
99. Qingdao Municipal Hospital: Houheng Su.
100. Wuhan Union Hospital Affiliated to Tongji Medical School of Huazhong University of Science and Technology: Lingxun Shen.
101. No. 264 Hospital of People’s Liberation Army: Jinli Ru, Xiaoxiang Xie.
102. Zhongda Hospital Affiliated to Southeast University: Meimei Wang.
103. The Central Hospital of Sichuan Mianyang: Jing Yang, yu zhang.
104. The Seventh People’s Hospital of Shenyang: Zhen Wang, Tienan Li.

Author Contributions

Conceptualization: X. Zeng.
Data curation: J. Zhao, Z. Wang.
Funding acquisition: X. Zeng.
Investigation: M. Zhang, J. Xu, L. Jiang, L. Gong, F. Wu, J. Gu, J. Zhao, Y. Zhao.
Methodology: Y. Xiang.
Project administration: M. Li, X. Zeng.
Writing – original draft: N. Jiang.
References

1. Li M, Zhang W, Leng X, Li Z, Ye Z, Li C, et al. Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus. 2013; 22(11): 1192–1199. https://doi.org/10.1177/0961203313499086 PMID: 23963101

2. Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015; 2(1): e000078. https://doi.org/10.1136/lupus-2014-000078 PMID: 25861458

3. Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev. 1993; 7(4): 199–207. https://doi.org/10.1016/0268-960x(93)90006-p PMID: 8130682

4. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5): 299–308.

5. González-Naranjo LA, Betancur OM, Alarcón GS, Ugarte-Gil MF, Jaramillo-Arooyave D, Wojdyla D, et al. Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Semin Arthritis Rheum. 2016; 45(6): 675–683. https://doi.org/10.1016/j.semarthrit.2015.11.003 PMID: 26698222

6. Fernández M, Alarcón GS, Apte M, Andrade RM, Vilá LM, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum. 2007; 56(2): 614–621. https://doi.org/10.1002/art.22376 PMID: 17265496

7. Patel N, Mody GM. Acute presentation of thrombocytopenia in systemic lupus erythematosus is associated with a high mortality in South Africa. Lupus. 2014; 23(2): 204–212. https://doi.org/10.1177/0961203313512009 PMID: 24213307

8. Jung JH, Soh MS, Ahn YH, Um YJ, Jung JY, Suh CH, et al. Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients. Medicine (Baltimore) 2016; 95(6): e2818.

9. Li M, Wang Q, Zhao J, Li Z, Ye Z, Li C, et al. Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus. 2014; 23(10): 1085–1091. https://doi.org/10.1177/0961203314527366 PMID: 24651670

10. Zhao J, Bai W, Zhu P, Zhang X, Liu S, Wu L, et al. Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus. Lupus. 2016; 25(6): 652–657. https://doi.org/10.1177/0961203315625460 PMID: 26762471

11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725.

12. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2): 288–291. PMID: 11838846

13. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol 2000; 27: 373–376. PMID: 10685799

14. Alger M, Aiarcon-Segovia D, Rivero SJ. Hemolytic anemia and thrombocytopenic purpura: two related subsets of systemic lupus erythematosus. J Rheumatol. 1977; 4: 351–357. PMID: 564405

15. Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol. 1985; 59:227–230. https://doi.org/10.1111/j.1365-2141.1985.tb02988.x PMID: 3970855

16. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford). 2003; 42: 230–234.

17. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 2005; 52: 4003–4010. https://doi.org/10.1002/art.21414 PMID: 16320348